MannKind Stock Surges 39% on New Drug Partnership

Stock Jumps on Ralinepag DPI Program Announcement

MannKind Corporation (MNKD) stock experienced a significant surge, climbing 39.28% in morning trading. The sharp increase followed the company's announcement of a new development program for a ralinepag dry powder inhalation (DPI) formulation, known as MNKD-1501, in partnership with United Therapeutics Corporation. Under the agreement, MannKind is eligible to receive up to $35 million in development milestones and a 10% royalty on net sales.

Overview of the Collaboration

This new program expands on a previous successful collaboration between the two companies. Their original 2018 agreement led to the FDA approval of Tyvaso DPI in May 2022, which generated $1.3 billion in revenue for United Therapeutics in 2025. This precedent provides investors with a framework for the potential of MNKD-1501, especially after United Therapeutics reported its Phase 3 ADVANCE OUTCOMES study for ralinepag tablets met its primary endpoint with high statistical significance. The announcement also marks a positive reversal in sentiment from February 2026, when a competing product from United Therapeutics caused a nearly 40% drop in MannKind's stock.

Market and Economic Impact

The stock's rally was supported by a constructive market backdrop, with the S&P 500, Dow Jones, and NASDAQ all showing gains, reflecting broad risk-on sentiment. Additional investor focus is driven by MannKind's upcoming first-quarter 2026 financial results, scheduled for release on May 6, 2026. Prior to this news, analyst coverage was mixed; H.C. Wainwright had lowered its price target to $8 while maintaining a Buy rating, and Leerink Partners held an Outperform rating.

Summary and Outlook

The combination of several powerful catalysts explains the sharp rise in MannKind's shares. The new agreement reframes the company's relationship with United Therapeutics as expansive rather than at risk. It includes a concrete $5 million near-term payment, a clear path to $35 million in milestones, and royalty potential from a drug candidate with a successful Phase 3 trial. These factors, combined with a rising market and an imminent earnings report, created a strong positive momentum for the stock.

FAQ

Q: Why did MannKind's stock price increase sharply?
A: The stock surged over 39% following the announcement of a new ralinepag dry powder inhaler (DPI) development program in partnership with United Therapeutics, which includes potential milestone payments of up to $35 million and 10% royalties.

Q: What is the significance of this partnership for MannKind?
A: This partnership reinforces a successful and profitable relationship with United Therapeutics, reversing previous concerns about competition and providing a clear pathway for future revenue tied to a drug with a positive Phase 3 trial outcome.

Source: Investing.com